PALATINE, Ill., May 12, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2017.
The Company reported net income of $0.4 million for the first quarter 2017 or $0.03 per diluted share, compared to net loss of $3.4 million or $0.28 per diluted share for the same period in 2016. Revenues for the quarter were $2.7 million compared to $0.2 million in the first quarter of 2016 reflecting the $2.5 million payment arising from the NEXAFED® and NEXAFED® SINUS licensing agreement with MainPointe Pharmaceuticals LLC.
